Quantification and Description of the Increase in Serum Troponin Following Acute Coronary Syndrome (QUANTUM)
The new assay of troponins T (highly sensitive troponins) detects concentrations much lower than before. Few data are currently available on their kinetics during acute coronary syndrome, especially in regard to the correlation with CK MB. The aim of the present study is to describe the kinetic of highly sensitive troponins in acute coronary syndrome, to correlate it with the concentration of CK MB, and possibly to evaluate their prognostic value with respect to infarct size .
Acute Coronary Syndrome
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Quantification and Description of the Increase in Serum Troponin Following Acute Coronary Syndrome|
|Study Start Date:||November 2012|
|Estimated Study Completion Date:||May 2013|
|Estimated Primary Completion Date:||May 2013 (Final data collection date for primary outcome measure)|
Patients who meet the inclusion criteria will have a highly sensitive troponins and CKMB assays q 8hr for the first day, and q 12h for the next 2 days. If clinically not indicated, the blood sample can be cancelled at any time, as in the case of a patient with an initial suspicion of acute coronary syndrome in which the final diagnosis is something else. Only patients with a definitive myocardial infarction will be analyzed.
Subgroup analyses includes ST-elevation MI, Non ST-elevation MI, revascularization vs no revascularization, procedural myocardial infarction.
Another analysis conducted is the correlation between the values of troponin and infarct size by echocardiography (in patients who have an echocardiography 2-7 days post AND 2-6 months post myocardial infarction)
|Contact: Paul Farand, MD MSc||(819) 346-1110 ext 9093 firstname.lastname@example.org|
|Contact: Francis Bonenfant, resident||(819) 346-1110 ext 4987 email@example.com|
|Centre Hospitalier Universitaire de Sherbrooke, departement de cardiologie|
|Sherbrooke, Quebec, Canada, J1H 5N4|
|Principal Investigator:||Paul Farand, Md MSc||Centre Hospitalier Universitaire de Sherbrooke|